Suzuki M - Search Results

1

Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers.

Komatsu M, Hiyama K, Tanimoto K, Yunokawa M, Otani K, Ohtaki M, Hiyama E, Kigawa J, Ohwada M, Suzuki M, Nagai N, Kudo Y, Nishiyama M. Komatsu M, et al. Among authors: suzuki m. Mol Cancer Ther. 2006 Mar;5(3):767-75. doi: 10.1158/1535-7163.MCT-05-0408. Mol Cancer Ther. 2006. PMID: 16546992

2

Involvement of microsatellite instability in lymph node metastasis of endometrial carcinoma.

Ohwada M, Suzuki M, Kohno T, Saga Y, Takei Y, Jobo T, Kuramoto H, Sato I. Ohwada M, et al. Among authors: suzuki m. Cancer Genet Cytogenet. 2002 Jan 15;132(2):152-5. doi: 10.1016/s0165-4608(01)00540-4. Cancer Genet Cytogenet. 2002. PMID: 11850079

3

Establishment of a new cell line (TAYA) of clear cell adenocarcinoma of the ovary and its radiosensitivity.

Saga Y, Suzuki M, Machida S, Ohwada M, Sato I. Saga Y, et al. Among authors: suzuki m. Oncology. 2002;62(2):180-4. doi: 10.1159/000048265. Oncology. 2002. PMID: 11914605

4

Unsuspected uterine carcinosarcoma (heterologous) diagnosed following conservative therapies with medroxyprogesterone acetate for presumed early-stage endometrial carcinoma.

Fujiwara H, Shibahara H, Usui R, Takamizawa S, Kosuge S, Ohwada M, Suzuki M, Sato I. Fujiwara H, et al. Among authors: suzuki m. Am J Reprod Immunol. 2002 Mar;47(3):129-31. doi: 10.1034/j.1600-0897.2002.1c068.x. Am J Reprod Immunol. 2002. PMID: 12069197 No abstract available.

5

Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.

Itamochi H, Kigawa J, Akeshima R, Sato S, Kamazawa S, Takahashi M, Kanamori Y, Suzuki M, Ohwada M, Terakawa N. Itamochi H, et al. Among authors: suzuki m. Oncology. 2002;62(4):349-53. doi: 10.1159/000065067. Oncology. 2002. PMID: 12138243

6

Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.

Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N. Itamochi H, et al. Among authors: suzuki m. Obstet Gynecol. 2002 Aug;100(2):281-7. doi: 10.1016/s0029-7844(02)02040-9. Obstet Gynecol. 2002. PMID: 12151151

7

Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.

Takano M, Kikuchi Y, Kita T, Suzuki M, Ohwada M, Yamamoto T, Yamamoto K, Inoue H, Shimizu K. Takano M, et al. Among authors: suzuki m. Anticancer Res. 2002 May-Jun;22(3):1833-8. Anticancer Res. 2002. PMID: 12168878 Clinical Trial.

8

PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy.

Kanamori Y, Kigawa J, Itamochi H, Sultana H, Suzuki M, Ohwada M, Kamura T, Sugiyama T, Kikuchi Y, Kita T, Fujiwara K, Terakawa N. Kanamori Y, et al. Among authors: suzuki m. Int J Cancer. 2002 Aug 20;100(6):686-9. doi: 10.1002/ijc.10542. Int J Cancer. 2002. PMID: 12209607

9

A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer.

Takei Y, Suzuki M, Ohwada M, Saga Y, Kohno T, Machida S, Sato I. Takei Y, et al. Among authors: suzuki m. Oncol Rep. 2003 Jul-Aug;10(4):951-5. Oncol Rep. 2003. PMID: 12792751 Clinical Trial.

10

Abnormal fragile histidine triad expression in advanced cervical cancer and evaluation of its utility as a prognostic factor.

Machida S, Ohwada M, Saga Y, Suzuki M. Machida S, et al. Among authors: suzuki m. Oncology. 2003;65(1):89-93. doi: 10.1159/000071209. Oncology. 2003. PMID: 12837987

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,504 results

Search Page

Filters